Press Release: Sanofi Foundation opens new chapter centered on future generations

Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases.

GlobeNewsWire • 4 hours ago

Sanofi Multiple Sclerosis Drug Gets EU Approval

The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.

WSJ • Jun 23, 2026

EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis

Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.

Zacks Investment Research • Jun 23, 2026

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.

GlobeNewsWire • Jun 23, 2026

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi a ppoints  Paulo Fontoura   as   Global  Head of  R&D Paris ,  June 22 ,   2026. Sanofi today announced the appointment of Paulo F o ntoura ,  MD, PhD, FAAN,   as  Executi v e Vice President, Global  Head of Research & Development  Pharma, effective September 1, 2026.

GlobeNewsWire • Jun 22, 2026

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

Zacks Investment Research • Jun 22, 2026

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IV Second global approval for Sarclisa SC following the EU Paris, June 19, 2026. The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma (MM).

GlobeNewsWire • Jun 19, 2026

Five International Dividend Growers Your Screen Is Distorting

Dividend growth streaks for international stocks can be distorted by exchange rates, payment cadence changes, and data errors, masking underlying business quality. A foreign company's dividend rises in US dollars only when its home currency's rise outpaces the currency's decline against the dollar. High dividend growth rates like those of Canadian National and Taiwan Semiconductor usually screen accurately, but smaller raises may show as cuts.

Seeking Alpha • Jun 16, 2026

Sanofi: Information concerning the total number of voting rights and shares – May 2026

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

GlobeNewsWire • Jun 15, 2026

Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children

SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.

Zacks Investment Research • Jun 15, 2026